Alemtuzumab pretreatment and tacrolimus monotherapy in living-donor liver and kidney transplantation

Abstract

We previously described the use of alemtuzumab as a pretreatment agent in 207 living-donor renal transplants, a trial that represented the largest series to date of live-donor renal and liver transplant recipients undergoing alemtuzumab pretreatment, and confirmed the short-term safety, efficacy and cost–effectiveness of this approach. This paper examines the use of the immunosuppressive combination of alemtuzumab and tacrolimus monotherapy in 47 patients with right-lobe adult living-donor liver transplantation.